24.90
-1.52 (-5.75%)
| Penutupan Terdahulu | 26.42 |
| Buka | 26.82 |
| Jumlah Dagangan | 284,205 |
| Purata Dagangan (3B) | 635,808 |
| Modal Pasaran | 1,895,629,440 |
| Harga / Jualan (P/S) | 2.61 |
| Harga / Buku (P/B) | 3.75 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Mar 2025 |
| Margin Operasi (TTM) | -8,344.08% |
| EPS Cair (TTM) | -15.87 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 45,500.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.03% |
| Nisbah Semasa (MRQ) | 35.30 |
| Aliran Tunai Operasi (OCF TTM) | -78.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -59.08 M |
| Pulangan Atas Aset (ROA TTM) | -15.02% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.18% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | CG Oncology, Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.38 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.28% |
| % Dimiliki oleh Institusi | 100.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Dec 2024 | 2,221,474 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 75.00 (HC Wainwright & Co., 201.21%) | Beli |
| Median | 65.00 (161.04%) | |
| Rendah | 55.00 (Morgan Stanley, 120.88%) | Beli |
| Purata | 65.00 (161.04%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 25.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Mar 2025 | 75.00 (201.20%) | Beli | 24.90 |
| 25 Mar 2025 | 75.00 (201.20%) | Beli | 27.54 | |
| Morgan Stanley | 07 Mar 2025 | 55.00 (120.88%) | Beli | 26.72 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |